Citi analyst Yigal Nochomovitz lowered the firm’s price target on Ideaya Biosciences to $58 from $60 and keeps a Buy rating on the shares. The analyst updated models in Smid-cap biotechnology following the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences removed from Analyst Focus List at JPMorgan
- Ideaya Biosciences price target lowered to $66 from $69 at JPMorgan
- Ideaya Biosciences price target lowered to $53 from $60 at Oppenheimer
- Ideaya Biosciences reports Q2 EPS (68c), consensus (53c)
- IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update